Stealth biotech Receptor Life Sciences raises $7.5M to develop inhalable plant-extract pharmaceuticals targeting pain, CNS and chemo side effects

Receptor Life Sciences, a stealthy Seattle-area biotech founded in 2015, raised just over $7.5 million and is developing inhalable pharmaceutical preparations derived from plant extracts to treat conditions including pain, CNS and metabolic and gastrointestinal disorders, and chemotherapy side effects. The company declined to name investors or disclose the specific plant, lists minimal public personnel, and had a USPTO appeal to trademark its name rejected.

No comments yet.